Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis

Neurological Sciences

Volumn 34, Issue 2, 2013, Pages 181-186

  Madeddu, Roberto ^a,c   Farace, Cristiano ^a   Tolu, Paola ^a   Solinas, Giuliana ^a   Asara, Yolande ^a   Sotgiu, Maria Alessandra ^a   Delogu, Lucia Gemma ^a   Prados, Jose Carlos ^b   Sotgiu, Stefano ^a   Montella, Andrea ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF GRANADA   (Spain)

^c NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Axonal damage; Biomarkers; Cerebrospinal fluid; Cytoskeletal proteins; Multiple sclerosis

Indexed keywords

BETA TUBULIN; BETA TUBULIN 2; BETA TUBULIN 3; BIOLOGICAL MARKER; CYTOSKELETON PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; ISOPROTEIN; NEUROFILAMENT LIGHT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADULT; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; PROGNOSIS; TUBULIN;

EID: 84876196550     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-012-0974-4     Document Type: Article

References (43)

1. Noseworthy JH, Lucchinetti C, Rodriguez M et al (2000) Multiple sclerosis. N Engl J Med 343:938-952
2. Alonso A, Hernán MA (2008) Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71:129-135
3. Hirtz D, Thurman DJ, Gwinn-Hardy K et al (2007) How common are the "common" neurologic disorders? Neurology 68:326-337
4. Orton SM, Herrera BN, Yee IM et al (2006) Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 5:932-936
5. Greer JM, McCombe PA (2011) Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol 234:7-18
6. Dyment DA, Ebers GC, Sadovnick AD (2004) Genetics of multiple sclerosis. Lancet Neurol 3(2):104-110
7. Ebers GC (2008) Environmental factors and multiple sclerosis. Lancet Neurol 7(3):268-277
8. Sotgiu S, Pugliatti M, Sanna A et al (2002) Multiple sclerosis complexity in selected populations: the challenge of Sardinia, insular Italy. Eur J Neurol 9:329-341
9. Pugliatti M, Rosati G, Carton H et al (2006) The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13:700-722
10. Budde MD, Kim JH, Liang HF et al (2008) Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis. NMR Biomed 21:589-597
11. Bitsch A, Schuchardt J, Bunkowski S et al (2000) Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 123:1174-1183
12. Rammohan KW (2003) Axonal injury in multiple sclerosis. Curr Neurol Neurosci Rep 3(3):231-237
13. Teunissen CE, Dijkstra PC, Polman C (2005) Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 4:32-41
14. Zaffaroni M (2003) Biological indicators of the neurodegenerative phase of multiple sclerosis. J Neurol Sci 24(Suppl 5):S279-S282
15. Lycke JN, Karlsson JE, Andersen O, Rosengren LE (1998) Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 64(3):402-404
16. Haghighi S, Andersen O, Odén A, Rosengren L (2004) Cerebrospinal fluid markers in MS patients and their healthy siblings. Acta Neurol Scand 109(2):97-99
17. Malmeström C, Haghighi S, Rosengren L et al (2003) Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 61(12):1720-1725
18. Norgren N, Rosengren L, Stigbrand T (2003) Elevated neurofilament levels in neurological diseases. Brain Res 987(1):25-31
19. Semra YK, Seidi OA, Sharief MK (2002) Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 122(1-2):132-139
20. Rosengren LE, Lycke J, Andersen O (1995) Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci 133(1-2):61-65
21. Petzold A, Eikelenboom MJ, Gveric D et al (2002) Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 125(Pt 7):1462-1473
22. Luduena RF (1998) Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 178:207-275
23. Sullivan KF, Cleveland DW (1986) Identification of conserved isotype defining variable region sequences for four vertebrate β-tubulin polypeptide classes. Proc Natl Acad Sci USA 83:4327-4331
24. Laferrière NB, MacRae TH, Brown DL (1997) Tubulin synthesis and assembly in differentiating neurons. Biochem Cell Biol 75(2):103-117
25. Hoffman PN, Cleveland DW (1988) Neurofilament and tubulin expression recapitulates the developmental program during axonal regeneration: induction of a specific beta-tubulin isotype. Proc Natl Acad Sci USA 85(12):4530-4533
26. Burgoyne RD, Cambray-Deakin MA, Lewis SA et al (1988) Differential distribution of beta-tubulin isotypes in cerebellum. EMBO J 7(8):2311-2319
27. Joshi HC, Cleveland DW (1989) Differential utilization of beta-tubulin isotypes in differentiating neurites. J Cell Biol 109(2):663-673
28. Lee MK, Rebhun LI, Frankfurter A (1990) Post-translational modification of class III beta-tubulin. Proc Natl Acad Sci USA 87(18):7195-7199
29. Moskowitz PF, Smith R, Pickett J et al (1993) Expression of the class III beta-tubulin gene during axonal regeneration of rat dorsal root ganglion neurons. J Neurosci Res 34(1):129-134
30. McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
31. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
32. Ziemann U, Wahl M, Hattingen E, Tumani H (2011) Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. Prog Neurobiol. doi: 10.1016/j.pneurobio.2011.04.007 (in press)
33. Tumani H, Hartung HP, Hemmer B et al (2009) Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 35(2):117-127
34. Bielekova B, Martin R (2004) Development of biomarkers in multiple sclerosis. Brain 127:1463-1478
35. Lucchinetti C, Brück W, Parisi J et al (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47(6):707-717
36. Hein K, Kohler A, Diem R et al (2008) Biological marker for axonal degeneration in CSF and blood of patient with the first event indicative for multiple sclerosis. Neurosci Lett 436:72-76
37. Bauer NG, Richter-Landsberg C et al (2009) Role of the oligodendroglial cytoskeleton in differentiation and myelination. Glia 57(16):1691-1705
38. Salzer J, Svenningsson A, Sundstrom P (2010) Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 16:287-292
39. Norgren N, Sundström P, Svenningsson A et al (2004) Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 63(9):1586-1590
40. Axelsson M, Malmeström C, Nilsson S et al (2010) Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol 258(5):882-888
41. Trapp BD, Bö L, Mörk S, Chang A (1999) Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 98(1):49-56
42. Gresle MM, Butzkueven H, Shaw G (2011) Neurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosis. Mult Scler Int 2011:315406. doi: 10.1155/2011/315406
43. Gunnarsson M, Malmestrom C, Axelsson M et al (2011) Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 69:83-89